AL HB463

Authorizes terminally ill patients to access investigational drugs, biological products, or devices that have completed phase 1 clinical trials but lack FDA approval, provided they meet specified eligibility requirements.

Requires eligible patients to have exhausted all FDA-approved treatment options, receive physician recommendation, and provide written informed consent that includes explanation of risks, potential outcomes, and financial liability.

Prohibits licensing boards and Medicare certification entities from sanctioning health care providers solely for recommending or providing access to experimental treatments consistent with medical standards of care.

Prevents state officials from blocking eligible patients' access to investigational treatments and shields manufacturers and healthcare providers from private lawsuits for harm resulting from the experimental treatment if acting in good faith and with reasonable care.

Clarifies that health insurers, hospitals, and government agencies are not required to cover costs associated with experimental treatment or provide additional services unless contractually or legally obligated.